Atlas Trials

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Clinical trial NCT03816332 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03816332
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8Metastatic Basal Cell CarcinomaMetastatic MelanomaMetastatic Merkel Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaPathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8
Start date
2019-11-08
Primary completion
2022-10-11
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.